NGM Biopharmaceuticals, Inc.

Equities

NGM

US62921N1054

Biotechnology & Medical Research

Real-time Estimate Cboe BZX 12:29:07 2024-03-28 pm EDT 5-day change 1st Jan Change
1.575 USD -2.78% Intraday chart for NGM Biopharmaceuticals, Inc. +0.96% +83.35%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
North American Morning Briefing : Investors -2- DJ
North American Morning Briefing : Stock Futures -2- DJ
Raymond James Downgrades NGM Biopharmaceuticals to Market Perform From Outperform MT
NGM Biopharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
NGM Biopharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 CI
North American Morning Briefing : Stock Futures -2- DJ
North American Morning Briefing : Fed's Preferred -2- DJ
B. Riley Lowers NGM Biopharmaceuticals' PT to $1.55 From $3.50 on Heels of Announced Sale Agreement With Affiliates of The Column Group, Keeps Buy Rating MT
TD Cowen Downgrades NGM Biopharmaceuticals to Market Perform From Outperform, Adjusts Price Target to $1.55 From $4 MT
Sector Update: Health Care Stocks Ease Late Afternoon MT
Sector Update: Health Care Stocks Weaker Monday Afternoon MT
Sector Update: Health Care MT
NGM Biopharmaceuticals Enters Merger Deal With Affiliates of The Column Group MT
Atlas Neon Parent, Inc. entered into a definitive Agreement to acquire an unknown majority stake in NGM Biopharmaceuticals, Inc. for approximately $140 million. CI
NGM Biopharmaceuticals Provides Update on Cancer Treatment Trial -- Shares Rise MT
NGM Bio Announces New Clinical Data from Ongoing Trial of Ngm707 in Advanced Solid Tumors and Outlines Evolved Strategy for Aldafermin and Ngm120 to Focus on Rare Conditions with Significant Unmet Need CI
NGM Biopharmaceuticals Stock Soars as Shareholder Group Expresses Takeover Interest MT
NGM Biopharmaceuticals Receives Non-Binding Expression of Interest from Column Group CI
NGM Biopharmaceuticals, Inc.(NasdaqGS:NGM) dropped from NASDAQ Biotechnology Index CI
B. Riley Lowers NGM Biopharmaceuticals' Price Target to $3.50 From $7, Maintains Buy Rating MT
NGM Biopharmaceuticals Says Phase 2b Trial of Potential Cirrhosis Treatment Meets Primary Endpoint MT
NGM Biopharmaceuticals, Inc. Presents Positive Phase 2b Results from the Alpha 4 Trial of Aldafermin in Patients with Compensated Cirrhosis (F4) Due to NASH at AASLD The Liver Meeting CI
NGM Biopharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Ngm Biopharmaceuticals, Inc. Appoints Irene Perlich as Principal Accounting Officer, Effective September 15, 2023 CI
NGM Biopharmaceuticals, Inc. Announces Appointment of Irene Perlich as Principal Accounting Officer, Effective September 15, 2023 CI
Chart NGM Biopharmaceuticals, Inc.
More charts
NGM Biopharmaceuticals, Inc. is a biopharmaceutical company. The Company's biology-driven and therapeutic area agnostic discovery engine has produced a diverse pipeline of product candidates spanning oncology, liver and metabolic disease and retinal disease. Its pipeline candidates include NGM707: ILT2/ILT4 Dual Antagonist Antibody for the Potential Treatment of Solid Tumors, Including microsatellite stable colorectal cancer patients; Aldafermin: Engineered Analog of Human Hormone FGF19 for the Potential Treatment of primary sclerosing cholangitis, and NGM120: glial cell-derived neurotrophic factor receptor alpha-like Antagonist for the Potential Treatment of Hyperemesis Gravidarum. It is conducting an open-label Phase 1/2 clinical trial evaluating NGM707 as a monotherapy and in combination with pembrolizumab for the treatment of patients with advanced or metastatic solid tumors. Its programs, NGM438 and NGM831, are being studied in a Phase 1/2 trial in combination with pembrolizumab.
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C-
More Ratings
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
5
Last Close Price
1.62 USD
Average target price
1.55 USD
Spread / Average Target
-4.32%
Consensus
  1. Stock
  2. Equities
  3. Stock NGM Biopharmaceuticals, Inc. - Nasdaq
  4. News NGM Biopharmaceuticals, Inc.
  5. Sector Update: Health Care Stocks Trade Higher Premarket Monday